Blog icon

More effective and targeted cancer therapies with improved patient outcomes.

There is an unmet need in multiple cancers for improved efficacy. Current treatments with antibody alone have led to poor patient responses, and not all ADCs function adequately.

Antibody drug conjugates (ADCs), which combine an antibody with chemotherapeutic drugs to make cancer treatment more targeted, effective and less damaging to healthy tissue, are set to work better than ever.

Our antibody-drug-polymer therapies, have improved efficacy and pharmacokinetics than current ADCs, thus lowering drug doses, they allow for use of multiple drugs and are expected to lead to fewer side effects.

Technology

  • Advanced biological‐polymeric materials to treat human disease
  • RAFT (reversible addition and fragmentation chain transfer) polymerisation technology leads to defined polymeric carriers with the ability to tailor composition and structure
  • Stable, safe, and reliable polymeric scaffold for attachment of biologically active compounds
  • Optimise the pharmacokinetic properties of therapeutic drugs and proteins
  • Outstanding efficacy and pharmacokinetics, in models of disease
  • Drug loaded antibody-polymer conjugates have performed well in animal models of cancer burden
  • Requires pharmaceutical or biotech partner to go to next stage.

Applications

  • Only three commercial ADC based drugs available in 2013, sales approx. USD450 million.
  • Applications across a range of diseases, extending towards diagnostic and imaging therapies
  • Available ADC drugs: Mylotarg (Pfizer), Adcetris (Seattle Genetics/Takeda), Kadcyla (Roche/Genentech)
  • With around 12 expected new ADC launches over the next 10 years, the overall market is expected to reach USD10.4 billion by 2024
  • Preferred model is industry partnership is a Joint Venture with pharmaceutical / biotech company.

Intellectual property

Patent filed January 2017 – Biocompatible and hydrophilic polymerconjugate for targeted delivery of an agent.

The team

Our team collectively has experience in organic chemistry, polymer chemistry, protein chemistry and bioconjugation. Our research interests include, methods to conjugate small molecules, or polymers to proteins such as antibodies or antibody fragments.

Could this technology provide you with a competitive edge?

Contact us to find out more about our licensing and investment options.

Other opportunities like this

  • A procedure that can take days can be reduced to around an hour through a new method that harvests stem cells for bone marrow donors and cancer patients.

  • An inexpensive and small unit for capturing carbon dioxide that is agile and readily deployable for different applications in heavy industries, food and beverage production, chemical manufacture, medical and construction.

  • Artificial silk production technology with potential applications for a range of markets.

Contact us

Find out how we can help you and your business. Get in touch using the form below and our experts will get in contact soon!

CSIRO will handle your personal information in accordance with the Privacy Act 1988 (Cth) and our Privacy Policy.


First name must be filled in

Surname must be filled in

I am representing *

Please choose an option

Please provide a subject for the enquriy

0 / 100

We'll need to know what you want to contact us about so we can give you an answer

0 / 1900

You shouldn't be able to see this field. Please try again and leave the field blank.